Print Page   |   Your Cart   |   Sign In   |   Join
News & Press: National News

NCPA Shines Spotlight on PBMs in Comments to FTC

Friday, December 8, 2017   (0 Comments)
Posted by: Janet Anderson
Share |

In comments submitted today to the Federal Trade Commission, the National Community Pharmacists Association details the problem of and proposed solutions to how pharmacy benefit managers distort the marketplace. NCPA submitted the comments after participating in a panel on competition in prescription drug markets at an FTC workshop last month.

 

“NCPA’s FTC comments attempt to accomplish two things: explain aspects of the PBM business model that should raise competitive red flags, and offer concrete steps the Commission can take in response,” said NCPA CEO B. Douglas Hoey, Pharmacist, MBA. “We believe the FTC is uniquely suited to help create a more competitive marketplace for delivering prescription drugs to patients and where access to these therapeutic remedies is robust.”  

NCPA described some structural flaws within the current system, which include:

  • PBMs’ lack of any fiduciary obligations to health plan sponsors or beneficiaries in spite of the fact that health plan sponsors rely on PBMs, particularly in the area of benefit design. This enables PBMs to operate without transparency that would enable plan sponsors and beneficiaries to determine PBM cost-effectiveness.
  • PBM contracts and negotiations with plan sponsors are one-sided and opaque, resulting in an inability for plan sponsors to navigate these complex and obtuse contracts or understand the downstream effects on patients and pharmacies.
  • PBMs have a conflict of interest in owning mail order and specialty pharmacies, while at the same time setting reimbursement rates for the retailers that compete with the PBM pharmacies. As a result, PBMs have created a less competitive marketplace, steering patients to their own pharmacies.  

NCPA’s comments offered four policy recommendations for the FTC, which include:

  • Support for the Department of Labor’s recommendation to require PBMs to disclose all direct and indirect compensation to ERISA plans to evaluate whether compensation to PBMs, pharmacies (including those owned by PBMs) and subcontractors are “reasonable.”
  • Collaboration with DOL to create a standardized definition of what constitutes “brand,” “generic,” “specialty,” and “rebate” for the purposes of eliminating confusion in ERISA drug plan designs.
  • Endorsement of federal and state transparency efforts surrounding PBM “maximum allowable cost” lists for generic prescription drugs.
  • Increased scrutiny of the conflicts of interest that can be attributed to PBMs operating as both a reimburser and competitor in the pharmacy marketplace. 

more Calendar

7/25/2018
Vaccinating Adults and Adolescents: An Immunization Program for Pharmacists

7/27/2018
Suicide Awareness and Referral for Pharmacy Professionals- Renton

8/7/2018
Webinar: USP 797 and 800 Review

Online Surveys
1402 - ICU Medical Inc Campaign
Association Management Software Powered by YourMembership  ::  Legal